## EMN: Eastman Chemical Company - XLB: Basic Materials

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 3.1% in lower entry zone (3.0-6.0%), top quartile (83rd pct) cross-sectional ranking. Short-term MRS_5 (0.2%) confirms momentum alignment. Caution: momentum weakening (-2.5% MRS).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($60.36)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. RBC Raises Price Target on Eastman Chemical to $74 From $71, Keeps Outperform Rating**
- Source: marketscreener.com | 20251216T123421 | Bullish | Relevance: 100%
- RBC has increased its price target for Eastman Chemical (EMN) to $74, up from $71, while maintaining an "Outperform" rating on the stock. This adjustment reflects continued confidence in the company's performance. The company also recently announced an increase in its quarterly dividend to $0.84 per share.

**2. Thrivent Financial for Lutherans Trims Stock Position in Eastman Chemical Company $EMN**
- Source: MarketBeat | 20251216T140751 | Somewhat-Bearish | Relevance: 100%
- Thrivent Financial for Lutherans significantly reduced its stake in Eastman Chemical Company (NYSE:EMN) by 39.9% in the second quarter, now holding 498,733 shares valued at approximately $37.24 million. This move comes as Eastman Chemical missed its quarterly earnings and revenue expectations, despite increasing its quarterly dividend to $0.84 per share. Various other institutional investors have recently adjusted their positions in the company, which maintains a "Moderate Buy" rating among analysts.

**3. Eastman, AstraZeneca, Kraft Heinz, and P&G Recognized with OMP Supply Chain Awards**
- Source: ACN Newswire | 20251216T140756 | Bullish | Relevance: 100%
- AstraZeneca, Eastman, Kraft Heinz, and P&G were honored at the OMP Conference in Miami for their outstanding contributions and commitment to innovation and excellence in supply chain planning. Eastman received the Long-Term Partnership Award for co-shaping Unison Planning, AstraZeneca won the Innovation Award for AI-driven planning, and Kraft Heinz and P&G were recognized with the Excellence Award for their sustained commitment to advancing digital supply chain planning. Philip Vervloesem, OMP's Chief Commercial and Markets Officer, commended all the winners for their achievements.

**4. Eastman, AstraZeneca, Kraft Heinz, and P&G Recognized with OMP Supply Chain Awards**
- Source: USA Today | 20251217T162557 | Bullish | Relevance: 88%
- Eastman, AstraZeneca, Kraft Heinz, and P&G were honored at the OMP Conference for their significant contributions to supply chain planning innovation and excellence. Eastman received the Long-Term Partnership Award for co-shaping Unison Planning™, AstraZeneca earned the Innovation Award for AI-driven planning, and Kraft Heinz and P&G were recognized with the Excellence Award for their sustained commitment to advancing digital supply chain planning. The awards highlight these companies' leadership in setting new industry benchmarks and driving real-world results.

**5. Is Albemarle’s 58.1% Rally in 2025 Justified by Its Lithium Growth Prospects?**
- Source: Simply Wall Street | 20251218T000919 | Neutral | Relevance: 62%
- Albemarle (NYSE: ALB) has seen a 58.1% rally year-to-date in 2025, sparking renewed interest due to shifting expectations for lithium demand. While a Discounted Cash Flow (DCF) analysis suggests the stock is fairly valued at around $140.11 per share, its Price to Sales (P/S) ratio of 3.21x is significantly higher than industry averages, indicating it may be overvalued based on current fundamentals. The article recommends using "Narratives" to incorporate individual investment perspectives on future lithium prices and growth into a more personalized valuation.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Citigroup | $72 | $70 | +3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 11 ($0.08M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 12.6% (-2.2%)
- Blackrock Inc.: 7.0% (+0.9%)
- State Street Corpora: 5.0% (+24.3%)
- Capital Research Glo: 3.7% (-1.0%)
- Dimensional Fund Adv: 3.5% (+14.4%)

### Key Risks

1. Valuation risk: PEG 3.9x with declining EPS estimates leaves no margin for error.
2. Long-term trend broken: trading 11.1% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.87 signals overvaluation risk, limited margin of safety. Forward P/E 10.3x attractive for 14% earnings growth. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $7.4B |
| Beta | 1.25 |
| 52W Range | $56.11 - $103.82 |
| Short Interest | 4.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.87 |
| Forward P/E | 10.3 |
| Current P/E | 11.8 |
| YoY Growth | 14.2% |
| EPS Direction | FALLING |

### Technicals

MRS_10 deteriorating from 5.6% to 3.1% (-2.5% in 5 days), indicating relative weakness vs NASDAQ. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 83rd percentile. MRS_5 at 0.2% confirms short-term momentum alignment. Below SMA200 (0.89x), long-term trend not supportive. RSI neutral at 57. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.08% (CS: 84) | Strong |
| RSI_14 | 57.4 | Neutral |
| MACD Histogram | 0.30 | Bullish |
| vs SMA20 | 1.035x | Above |
| vs SMA50 | 1.048x | Above |
| vs SMA200 | 0.889x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $64.12
- **Stop Loss:** $60.36 (5.9% risk)
- **Target:** $69.76 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 303
- **Position Value:** $19,428.36
- **Portfolio %:** 19.43%
- **Risk Dollars:** $1,140.00
- **Risk Per Trade:** 1.14%
- **Modifiers:** L1 95% | L2 120% | Combined 1.14x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-01-29 (Est: $0.81)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.17 | $1.14 | -2.2% |
| 2025Q2 | $1.75 | $1.60 | -8.7% |
| 2025Q1 | $1.89 | $1.91 | +1.2% |
| 2024Q4 | $1.57 | $1.87 | +18.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*